Business
enVVeno Medical Announces New U.S. VenoValve(R) Patent
- Expanding patent portfolio bolsters protection of the Company's lead product-The VenoValve is a potential first-in-class treatment for patients suffering
About this update from Envveno Medical Corporation
[{"type":"text","content":"- Expanding patent portfolio bolsters protection of the Company's lead product-The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg- There are currently no effective treatments for patients with deep venous CVI- The VenoValve is currently being evaluated in leading hospitals throughout the U.S. in the ongoing SAVVE U.S pivotal trialIRVINE, CA / ACCESSWIRE / April 11, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (\"enVVeno\" or the \"Company\"), a company setting new standards of care for the treatment of venous disease, today announced that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 11,285,243 titled, \"Biological valve for venous insufficiency,\" covering the method of manufacturing of the tissue portion of the VenoValve® bioprosthetic valve, the Company's lead product. The previously issued U.S. patent covers the VenoValve frame.\"We have invested a significant amount of time and energy over the past few years in formulating and executing an aggressive strategy to build a robust patent portfolio around the VenoValve and will continue to file new patent applications both in the U.S. and around the world as we continue to execute that strategy,\" commented enVVeno Medical CEO, Robert Berman. \"Our efforts are just beginning to yield positive results and we expect to see a significant increase in the frequency of newly issued VenoValve patents both inside and outside of the U.S.\"The VenoValve is a first-in-class surgically implanted currently undergoing the SAVVE U.S. pivotal trial for safety and effectiveness as a treatment of deep venous Chronic Venous Insufficiency (CVI). The VenoValve is intended to restore proper directional blood flow for patients with CVI of the deep veins of the leg. CVI occurs when the natural valves inside of the veins fail, causing blood to flow in the wrong direction (reflux), and creating increased pressure inside of the veins of the leg (venous hypertension).CVI can cause the leg to swell, and blood vessels to break, resulting in discoloration, pain, and the breakdown of the skin leading to venous ulcers (open sores) which are difficult to heal. Patients with severe CVI have limited mobility and often experience difficulty standing, walking, and completing everyday tasks. The Com...